Loading…

Prevalence of SARS-COV-2 infection and outcomes in Greek sarcoidosis patients

There is limited data on the prevalence of SARS-COV-2 in sarcoidosis patients and the underlying parameters linked to severity. We aimed to conduct a national multicenter study to explore the prevalence of SARS-COV-2 in sarcoidosis patients and investigate its impact on hospitalization and infection...

Full description

Saved in:
Bibliographic Details
Published in:Sarcoidosis, vasculitis, and diffuse lung diseases vasculitis, and diffuse lung diseases, 2024-12, Vol.41 (4), p.e2024055
Main Authors: Kotsiou, Ourania, Kirgou, Paraskevi, Tzouvelekis, Argyrios, Kolilekas, Lykourgos, Manali, Effrosyni, Papiris, Spyros, Papakosta, Despina, Antoniou, Katerina, Papanikolaou, Ilias, Steiropoulos, Paschalis, Tomos, Ioannis, Karampitsakos, Theodoros, Levounets, Anastasia, Fouka, Evagelia, Spyropoulos, Georgios, Mastrodimou, Semeli, Papaioannou, Ourania, Kallieri, Maria, Kosmidou, Nikoleta, Bizymi, Nikoleta, Zikos, Nikolaos, Dimeas, Ilias, Malli, Foteini, Daniil, Zoe
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 4
container_start_page e2024055
container_title Sarcoidosis, vasculitis, and diffuse lung diseases
container_volume 41
creator Kotsiou, Ourania
Kirgou, Paraskevi
Tzouvelekis, Argyrios
Kolilekas, Lykourgos
Manali, Effrosyni
Papiris, Spyros
Papakosta, Despina
Antoniou, Katerina
Papanikolaou, Ilias
Steiropoulos, Paschalis
Tomos, Ioannis
Karampitsakos, Theodoros
Levounets, Anastasia
Fouka, Evagelia
Spyropoulos, Georgios
Mastrodimou, Semeli
Papaioannou, Ourania
Kallieri, Maria
Kosmidou, Nikoleta
Bizymi, Nikoleta
Zikos, Nikolaos
Dimeas, Ilias
Malli, Foteini
Daniil, Zoe
description There is limited data on the prevalence of SARS-COV-2 in sarcoidosis patients and the underlying parameters linked to severity. We aimed to conduct a national multicenter study to explore the prevalence of SARS-COV-2 in sarcoidosis patients and investigate its impact on hospitalization and infection rates, describe the characteristics of the infected population and assess the role of these characteristics in determining the likelihood of infection or hospitalization. We recruited all the adult sarcoidosis patients with who were examined across eight Greek Health Interstitial Lung Disease Referral Centers from the beginning of the pandemic until August 1, 2022. All the data was collected using structured questionnaires. 530 sarcoidosis patients with a mean age of 54±12 years, 60% of whom were females, were recruited. 43% of them were under corticosteroid treatment, and 39% were under additional immunosuppression. 18% of Greek sarcoidosis patients were infected by the virus, which is a lower rate than the general population. The infection was mainly mild. Only one-fifth of the infected sarcoidosis patients required hospitalization, and no deaths or ICU admissions were recorded. Vaccination was found to be associated with a reduced likelihood of infection. Younger age, a longer period since diagnosis, abnormal PET-CT findings, and immunosuppression were associated with an increased probability of infection. The COVID-19 infection rate among Greek sarcoidosis patients was lower than the general population. Fewer than 20% needed hospitalization. There were no deaths or ICU admissions. Vaccination reduces the likelihood of infection. Younger age, longer diagnosis, abnormal PET-CT findings, and immunosuppression increased the chance of infection.
doi_str_mv 10.36141/svdld.v41i4.15661
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_3146611521</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3146611521</sourcerecordid><originalsourceid>FETCH-LOGICAL-p561-e4f9a4b10959fe67aaeb9d47dc0da65c66323ba25dd5d3e859d116373c66943c3</originalsourceid><addsrcrecordid>eNpNkE1Lw0AYhBdRbK3-AQ-yRy-p-2Y_0j2WolWoVGwRb2Gz-wZWk2zMJgX_vQEreJph5mEOQ8g1sDlXIOAuHlzl5gcBXsxBKgUnZJpKniaQ6ffTf35CLmL8YEwtJGPnZMK1klJqmJLnlw4PpsLGIg0l3S1fd8lq-5ak1Dcl2t6HhprG0TD0NtQYx5iuO8RPGk1ng3ch-khb03ts-nhJzkpTRbw66ozsH-73q8dks10_rZabpJUKEhSlNqIApqUuUWXGYKGdyJxlzihpleIpL0wqnZOO40JqB6B4xsdGC275jNz-zrZd-Bow9nnto8WqMg2GIeYcxHgGyBRG9OaIDkWNLm87X5vuO_97gP8AFp5ehw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3146611521</pqid></control><display><type>article</type><title>Prevalence of SARS-COV-2 infection and outcomes in Greek sarcoidosis patients</title><source>Open Access: PubMed Central</source><creator>Kotsiou, Ourania ; Kirgou, Paraskevi ; Tzouvelekis, Argyrios ; Kolilekas, Lykourgos ; Manali, Effrosyni ; Papiris, Spyros ; Papakosta, Despina ; Antoniou, Katerina ; Papanikolaou, Ilias ; Steiropoulos, Paschalis ; Tomos, Ioannis ; Karampitsakos, Theodoros ; Levounets, Anastasia ; Fouka, Evagelia ; Spyropoulos, Georgios ; Mastrodimou, Semeli ; Papaioannou, Ourania ; Kallieri, Maria ; Kosmidou, Nikoleta ; Bizymi, Nikoleta ; Zikos, Nikolaos ; Dimeas, Ilias ; Malli, Foteini ; Daniil, Zoe</creator><creatorcontrib>Kotsiou, Ourania ; Kirgou, Paraskevi ; Tzouvelekis, Argyrios ; Kolilekas, Lykourgos ; Manali, Effrosyni ; Papiris, Spyros ; Papakosta, Despina ; Antoniou, Katerina ; Papanikolaou, Ilias ; Steiropoulos, Paschalis ; Tomos, Ioannis ; Karampitsakos, Theodoros ; Levounets, Anastasia ; Fouka, Evagelia ; Spyropoulos, Georgios ; Mastrodimou, Semeli ; Papaioannou, Ourania ; Kallieri, Maria ; Kosmidou, Nikoleta ; Bizymi, Nikoleta ; Zikos, Nikolaos ; Dimeas, Ilias ; Malli, Foteini ; Daniil, Zoe</creatorcontrib><description>There is limited data on the prevalence of SARS-COV-2 in sarcoidosis patients and the underlying parameters linked to severity. We aimed to conduct a national multicenter study to explore the prevalence of SARS-COV-2 in sarcoidosis patients and investigate its impact on hospitalization and infection rates, describe the characteristics of the infected population and assess the role of these characteristics in determining the likelihood of infection or hospitalization. We recruited all the adult sarcoidosis patients with who were examined across eight Greek Health Interstitial Lung Disease Referral Centers from the beginning of the pandemic until August 1, 2022. All the data was collected using structured questionnaires. 530 sarcoidosis patients with a mean age of 54±12 years, 60% of whom were females, were recruited. 43% of them were under corticosteroid treatment, and 39% were under additional immunosuppression. 18% of Greek sarcoidosis patients were infected by the virus, which is a lower rate than the general population. The infection was mainly mild. Only one-fifth of the infected sarcoidosis patients required hospitalization, and no deaths or ICU admissions were recorded. Vaccination was found to be associated with a reduced likelihood of infection. Younger age, a longer period since diagnosis, abnormal PET-CT findings, and immunosuppression were associated with an increased probability of infection. The COVID-19 infection rate among Greek sarcoidosis patients was lower than the general population. Fewer than 20% needed hospitalization. There were no deaths or ICU admissions. Vaccination reduces the likelihood of infection. Younger age, longer diagnosis, abnormal PET-CT findings, and immunosuppression increased the chance of infection.</description><identifier>ISSN: 2532-179X</identifier><identifier>EISSN: 2532-179X</identifier><identifier>DOI: 10.36141/svdld.v41i4.15661</identifier><identifier>PMID: 39655591</identifier><language>eng</language><publisher>Italy</publisher><ispartof>Sarcoidosis, vasculitis, and diffuse lung diseases, 2024-12, Vol.41 (4), p.e2024055</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39655591$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kotsiou, Ourania</creatorcontrib><creatorcontrib>Kirgou, Paraskevi</creatorcontrib><creatorcontrib>Tzouvelekis, Argyrios</creatorcontrib><creatorcontrib>Kolilekas, Lykourgos</creatorcontrib><creatorcontrib>Manali, Effrosyni</creatorcontrib><creatorcontrib>Papiris, Spyros</creatorcontrib><creatorcontrib>Papakosta, Despina</creatorcontrib><creatorcontrib>Antoniou, Katerina</creatorcontrib><creatorcontrib>Papanikolaou, Ilias</creatorcontrib><creatorcontrib>Steiropoulos, Paschalis</creatorcontrib><creatorcontrib>Tomos, Ioannis</creatorcontrib><creatorcontrib>Karampitsakos, Theodoros</creatorcontrib><creatorcontrib>Levounets, Anastasia</creatorcontrib><creatorcontrib>Fouka, Evagelia</creatorcontrib><creatorcontrib>Spyropoulos, Georgios</creatorcontrib><creatorcontrib>Mastrodimou, Semeli</creatorcontrib><creatorcontrib>Papaioannou, Ourania</creatorcontrib><creatorcontrib>Kallieri, Maria</creatorcontrib><creatorcontrib>Kosmidou, Nikoleta</creatorcontrib><creatorcontrib>Bizymi, Nikoleta</creatorcontrib><creatorcontrib>Zikos, Nikolaos</creatorcontrib><creatorcontrib>Dimeas, Ilias</creatorcontrib><creatorcontrib>Malli, Foteini</creatorcontrib><creatorcontrib>Daniil, Zoe</creatorcontrib><title>Prevalence of SARS-COV-2 infection and outcomes in Greek sarcoidosis patients</title><title>Sarcoidosis, vasculitis, and diffuse lung diseases</title><addtitle>Sarcoidosis Vasc Diffuse Lung Dis</addtitle><description>There is limited data on the prevalence of SARS-COV-2 in sarcoidosis patients and the underlying parameters linked to severity. We aimed to conduct a national multicenter study to explore the prevalence of SARS-COV-2 in sarcoidosis patients and investigate its impact on hospitalization and infection rates, describe the characteristics of the infected population and assess the role of these characteristics in determining the likelihood of infection or hospitalization. We recruited all the adult sarcoidosis patients with who were examined across eight Greek Health Interstitial Lung Disease Referral Centers from the beginning of the pandemic until August 1, 2022. All the data was collected using structured questionnaires. 530 sarcoidosis patients with a mean age of 54±12 years, 60% of whom were females, were recruited. 43% of them were under corticosteroid treatment, and 39% were under additional immunosuppression. 18% of Greek sarcoidosis patients were infected by the virus, which is a lower rate than the general population. The infection was mainly mild. Only one-fifth of the infected sarcoidosis patients required hospitalization, and no deaths or ICU admissions were recorded. Vaccination was found to be associated with a reduced likelihood of infection. Younger age, a longer period since diagnosis, abnormal PET-CT findings, and immunosuppression were associated with an increased probability of infection. The COVID-19 infection rate among Greek sarcoidosis patients was lower than the general population. Fewer than 20% needed hospitalization. There were no deaths or ICU admissions. Vaccination reduces the likelihood of infection. Younger age, longer diagnosis, abnormal PET-CT findings, and immunosuppression increased the chance of infection.</description><issn>2532-179X</issn><issn>2532-179X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpNkE1Lw0AYhBdRbK3-AQ-yRy-p-2Y_0j2WolWoVGwRb2Gz-wZWk2zMJgX_vQEreJph5mEOQ8g1sDlXIOAuHlzl5gcBXsxBKgUnZJpKniaQ6ffTf35CLmL8YEwtJGPnZMK1klJqmJLnlw4PpsLGIg0l3S1fd8lq-5ak1Dcl2t6HhprG0TD0NtQYx5iuO8RPGk1ng3ch-khb03ts-nhJzkpTRbw66ozsH-73q8dks10_rZabpJUKEhSlNqIApqUuUWXGYKGdyJxlzihpleIpL0wqnZOO40JqB6B4xsdGC275jNz-zrZd-Bow9nnto8WqMg2GIeYcxHgGyBRG9OaIDkWNLm87X5vuO_97gP8AFp5ehw</recordid><startdate>20241210</startdate><enddate>20241210</enddate><creator>Kotsiou, Ourania</creator><creator>Kirgou, Paraskevi</creator><creator>Tzouvelekis, Argyrios</creator><creator>Kolilekas, Lykourgos</creator><creator>Manali, Effrosyni</creator><creator>Papiris, Spyros</creator><creator>Papakosta, Despina</creator><creator>Antoniou, Katerina</creator><creator>Papanikolaou, Ilias</creator><creator>Steiropoulos, Paschalis</creator><creator>Tomos, Ioannis</creator><creator>Karampitsakos, Theodoros</creator><creator>Levounets, Anastasia</creator><creator>Fouka, Evagelia</creator><creator>Spyropoulos, Georgios</creator><creator>Mastrodimou, Semeli</creator><creator>Papaioannou, Ourania</creator><creator>Kallieri, Maria</creator><creator>Kosmidou, Nikoleta</creator><creator>Bizymi, Nikoleta</creator><creator>Zikos, Nikolaos</creator><creator>Dimeas, Ilias</creator><creator>Malli, Foteini</creator><creator>Daniil, Zoe</creator><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20241210</creationdate><title>Prevalence of SARS-COV-2 infection and outcomes in Greek sarcoidosis patients</title><author>Kotsiou, Ourania ; Kirgou, Paraskevi ; Tzouvelekis, Argyrios ; Kolilekas, Lykourgos ; Manali, Effrosyni ; Papiris, Spyros ; Papakosta, Despina ; Antoniou, Katerina ; Papanikolaou, Ilias ; Steiropoulos, Paschalis ; Tomos, Ioannis ; Karampitsakos, Theodoros ; Levounets, Anastasia ; Fouka, Evagelia ; Spyropoulos, Georgios ; Mastrodimou, Semeli ; Papaioannou, Ourania ; Kallieri, Maria ; Kosmidou, Nikoleta ; Bizymi, Nikoleta ; Zikos, Nikolaos ; Dimeas, Ilias ; Malli, Foteini ; Daniil, Zoe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p561-e4f9a4b10959fe67aaeb9d47dc0da65c66323ba25dd5d3e859d116373c66943c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kotsiou, Ourania</creatorcontrib><creatorcontrib>Kirgou, Paraskevi</creatorcontrib><creatorcontrib>Tzouvelekis, Argyrios</creatorcontrib><creatorcontrib>Kolilekas, Lykourgos</creatorcontrib><creatorcontrib>Manali, Effrosyni</creatorcontrib><creatorcontrib>Papiris, Spyros</creatorcontrib><creatorcontrib>Papakosta, Despina</creatorcontrib><creatorcontrib>Antoniou, Katerina</creatorcontrib><creatorcontrib>Papanikolaou, Ilias</creatorcontrib><creatorcontrib>Steiropoulos, Paschalis</creatorcontrib><creatorcontrib>Tomos, Ioannis</creatorcontrib><creatorcontrib>Karampitsakos, Theodoros</creatorcontrib><creatorcontrib>Levounets, Anastasia</creatorcontrib><creatorcontrib>Fouka, Evagelia</creatorcontrib><creatorcontrib>Spyropoulos, Georgios</creatorcontrib><creatorcontrib>Mastrodimou, Semeli</creatorcontrib><creatorcontrib>Papaioannou, Ourania</creatorcontrib><creatorcontrib>Kallieri, Maria</creatorcontrib><creatorcontrib>Kosmidou, Nikoleta</creatorcontrib><creatorcontrib>Bizymi, Nikoleta</creatorcontrib><creatorcontrib>Zikos, Nikolaos</creatorcontrib><creatorcontrib>Dimeas, Ilias</creatorcontrib><creatorcontrib>Malli, Foteini</creatorcontrib><creatorcontrib>Daniil, Zoe</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Sarcoidosis, vasculitis, and diffuse lung diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kotsiou, Ourania</au><au>Kirgou, Paraskevi</au><au>Tzouvelekis, Argyrios</au><au>Kolilekas, Lykourgos</au><au>Manali, Effrosyni</au><au>Papiris, Spyros</au><au>Papakosta, Despina</au><au>Antoniou, Katerina</au><au>Papanikolaou, Ilias</au><au>Steiropoulos, Paschalis</au><au>Tomos, Ioannis</au><au>Karampitsakos, Theodoros</au><au>Levounets, Anastasia</au><au>Fouka, Evagelia</au><au>Spyropoulos, Georgios</au><au>Mastrodimou, Semeli</au><au>Papaioannou, Ourania</au><au>Kallieri, Maria</au><au>Kosmidou, Nikoleta</au><au>Bizymi, Nikoleta</au><au>Zikos, Nikolaos</au><au>Dimeas, Ilias</au><au>Malli, Foteini</au><au>Daniil, Zoe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of SARS-COV-2 infection and outcomes in Greek sarcoidosis patients</atitle><jtitle>Sarcoidosis, vasculitis, and diffuse lung diseases</jtitle><addtitle>Sarcoidosis Vasc Diffuse Lung Dis</addtitle><date>2024-12-10</date><risdate>2024</risdate><volume>41</volume><issue>4</issue><spage>e2024055</spage><pages>e2024055-</pages><issn>2532-179X</issn><eissn>2532-179X</eissn><abstract>There is limited data on the prevalence of SARS-COV-2 in sarcoidosis patients and the underlying parameters linked to severity. We aimed to conduct a national multicenter study to explore the prevalence of SARS-COV-2 in sarcoidosis patients and investigate its impact on hospitalization and infection rates, describe the characteristics of the infected population and assess the role of these characteristics in determining the likelihood of infection or hospitalization. We recruited all the adult sarcoidosis patients with who were examined across eight Greek Health Interstitial Lung Disease Referral Centers from the beginning of the pandemic until August 1, 2022. All the data was collected using structured questionnaires. 530 sarcoidosis patients with a mean age of 54±12 years, 60% of whom were females, were recruited. 43% of them were under corticosteroid treatment, and 39% were under additional immunosuppression. 18% of Greek sarcoidosis patients were infected by the virus, which is a lower rate than the general population. The infection was mainly mild. Only one-fifth of the infected sarcoidosis patients required hospitalization, and no deaths or ICU admissions were recorded. Vaccination was found to be associated with a reduced likelihood of infection. Younger age, a longer period since diagnosis, abnormal PET-CT findings, and immunosuppression were associated with an increased probability of infection. The COVID-19 infection rate among Greek sarcoidosis patients was lower than the general population. Fewer than 20% needed hospitalization. There were no deaths or ICU admissions. Vaccination reduces the likelihood of infection. Younger age, longer diagnosis, abnormal PET-CT findings, and immunosuppression increased the chance of infection.</abstract><cop>Italy</cop><pmid>39655591</pmid><doi>10.36141/svdld.v41i4.15661</doi></addata></record>
fulltext fulltext
identifier ISSN: 2532-179X
ispartof Sarcoidosis, vasculitis, and diffuse lung diseases, 2024-12, Vol.41 (4), p.e2024055
issn 2532-179X
2532-179X
language eng
recordid cdi_proquest_miscellaneous_3146611521
source Open Access: PubMed Central
title Prevalence of SARS-COV-2 infection and outcomes in Greek sarcoidosis patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T04%3A31%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20SARS-COV-2%20infection%20and%20outcomes%20in%20Greek%20sarcoidosis%20patients&rft.jtitle=Sarcoidosis,%20vasculitis,%20and%20diffuse%20lung%20diseases&rft.au=Kotsiou,%20Ourania&rft.date=2024-12-10&rft.volume=41&rft.issue=4&rft.spage=e2024055&rft.pages=e2024055-&rft.issn=2532-179X&rft.eissn=2532-179X&rft_id=info:doi/10.36141/svdld.v41i4.15661&rft_dat=%3Cproquest_pubme%3E3146611521%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p561-e4f9a4b10959fe67aaeb9d47dc0da65c66323ba25dd5d3e859d116373c66943c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3146611521&rft_id=info:pmid/39655591&rfr_iscdi=true